Literature DB >> 28923179

Drugs and hyperglycemia: A practical guide.

Vandana Jain1, Ronak Kumar Patel2, Zaureen Kapadia2, Sneha Galiveeti2, Maryann Banerji2, Lisel Hope2.   

Abstract

Drug-induced diabetes is one of the factors contributing to the increasing incidence of diabetes worldwide. This review considers the frequency, pathogenesis and treatment of drug-induced diabetes. Drugs that induce diabetes include hormonal therapy, especially glucocorticoids and androgen blockers, cardiovascular drugs, especially statins, beta-blockers and diuretics, antipsychotics, especially clozapine, olanzapine and quetiapine, antiretrovirals (protease inhibitors and non-reverse transcriptase inhibitors - NRTIs) and other drugs (mechanistic target of rapamycin inhibitors -mTORs, post organ transplantation drugs, tyrosine kinase inhibitors and interferon-alpha). Abnormalities of the distal gluco-regulatory pathways of hyperglycemia involve decreased insulin secretion and frequent insulin resistance, whereas the proximal defects are unknown, thus limiting targeted treatment. Drug-induced diabetes is potentially reversible and the risk is underestimated. There is little information on its long-term effects on microvascular complications as clinical trials have not been long enough and neither have they focused on these factors. Overall management includes awareness of a drug's diabetogenic potential, underlying diabetes risk, benefits and risks of continuing vs discontinuing the drug, plus a consideration of drug duration and dose. While diabetes and its severity can be identified and controlled, the likelihood of future diabetes complications frequently cannot. This, balanced against the predicted benefit of the drug, results in clinical uncertainty. Empirical approaches to drug-related hyperglycemia include decreasing the dose or selecting an alternative treatment, if possible. In the absence of drug-specific evidence, treatment of drug-induced hyperglycemia and diabetes is similar to comprehensive standard diabetes care, including lifestyle modifications, oral/injectable antidiabetic agents and insulin. Important clinical considerations include surveillance of glucose before and during treatment and, in some cases, institution of diabetes preventive measures like lifestyle modification and early treatment. Future research is needed to elucidate pathophysiology and optimal targeted treatment for drug-induced diabetes and its long-term complications. Published by Elsevier B.V.

Entities:  

Keywords:  Drug-induced diabetes; Drugs; Hyperglycemia; Medication; New-onset diabetes

Mesh:

Year:  2017        PMID: 28923179     DOI: 10.1016/j.maturitas.2017.08.006

Source DB:  PubMed          Journal:  Maturitas        ISSN: 0378-5122            Impact factor:   4.342


  8 in total

Review 1.  Pancreas and Adverse Drug Reactions: A Literature Review.

Authors:  Konrad Sosnowski; Piotr Nehring; Adam Przybyłkowski
Journal:  Drug Saf       Date:  2022-07-05       Impact factor: 5.228

2.  Brentuximab vedotin-associated diabetic ketoacidosis: a case report.

Authors:  Damla Köksalan; Mehmet Sözen; Alev Selek; Emre Gezer; Zeynep Cantürk; Berrin Çetinarslan
Journal:  Int J Diabetes Dev Ctries       Date:  2022-07-16

3.  PXR activation impairs hepatic glucose metabolism partly via inhibiting the HNF4α-GLUT2 pathway.

Authors:  Peihua Liu; Ling Jiang; Weimin Kong; Qiushi Xie; Ping Li; Xiaonan Liu; Jiayi Zhang; Ming Liu; Zhongjian Wang; Liang Zhu; Hanyu Yang; Ying Zhou; Jianjun Zou; Xiaodong Liu; Li Liu
Journal:  Acta Pharm Sin B       Date:  2021-10-16       Impact factor: 14.903

4.  The effect of a ketogenic diet and synergy with rapamycin in a mouse model of breast cancer.

Authors:  Yiyu Zou; Susan Fineberg; Alexander Pearlman; Richard D Feinman; Eugene J Fine
Journal:  PLoS One       Date:  2020-12-03       Impact factor: 3.240

5.  Olanzapine attenuates postoperative cognitive dysfunction in adult rats.

Authors:  Keitaro Tachi; Taeko Fukuda; Makoto Tanaka
Journal:  Heliyon       Date:  2021-02-12

Review 6.  A Scoping Review on the Reported Evidence and Gaps of the Risk of Diabetes in Dyslipidemic Patients under Statin Therapy.

Authors:  Jyotsna Needamangalam Balaji; Sreenidhi Prakash; Ashish Joshi; Krishna Mohan Surapaneni
Journal:  Clin Pract       Date:  2022-07-18

7.  Potential drug-drug interactions in drug therapy for older adults with chronic coronary syndrome at hospital discharge: A real-world study.

Authors:  Mei Zhao; Chuan-Fen Liu; Yu-Fei Feng; Hong Chen
Journal:  Front Pharmacol       Date:  2022-08-24       Impact factor: 5.988

8.  Successful treatment of hyperglycemia with liraglutide in a hospitalized 27-year-old patient with schizophrenia: A case report.

Authors:  Lei Zhang; Wen-Juan Yu; Hui Zhu; Hua-Fang Li; Jie Qiao
Journal:  World J Clin Cases       Date:  2022-07-26       Impact factor: 1.534

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.